Abstract
The hypertensive disorders of pregnancy complicate 5-10% of pregnancies. Of these disorders 70% are pregnancy related (preeclampsia-eclampsia and gestation hypertension) and 30 % are a pre-existing hypertensive condition (chronic hypertension). These disorders are associated with maternal and fetal complications and have a substantial economic impact. This review examined the pharmacological treatment of the hypertensive disorders of pregnancy. There is a general consensus that anti-hypertensive should be given with severe hypertension and this should be in the hospital. The value of antihypertensive drugs in pregnant women with mild hypertension continues to be an area of debate that the evidence is too scanty to securely evaluate the clinical benefits of treating mild hypertension during pregnancy. The choice of the antihypertensive agents depends on individual clinician preference, the specified maternal and foetal benefits and the reproductive complications (teratogenisity, fetotoxicity and neonatal toxicity) of each particular agent. There are unequivocal evidences that Magnesium sulphate is superior to other agents in reducing recurrent eclamptic seizures. There is a strong recent evidence recommended that magnesium sulphate should be considered for women with pre-eclampsia for whom there is concern about the risk of eclampsia.
Keywords: Hypertension, eclampsia, teratogenisity, fetotoxicity
Current Pharmaceutical Design
Title: Pharmacological Treatment of Hypertension in Pregnancy
Volume: 9 Issue: 21
Author(s): Y. Afifi and D. Churchill
Affiliation:
Keywords: Hypertension, eclampsia, teratogenisity, fetotoxicity
Abstract: The hypertensive disorders of pregnancy complicate 5-10% of pregnancies. Of these disorders 70% are pregnancy related (preeclampsia-eclampsia and gestation hypertension) and 30 % are a pre-existing hypertensive condition (chronic hypertension). These disorders are associated with maternal and fetal complications and have a substantial economic impact. This review examined the pharmacological treatment of the hypertensive disorders of pregnancy. There is a general consensus that anti-hypertensive should be given with severe hypertension and this should be in the hospital. The value of antihypertensive drugs in pregnant women with mild hypertension continues to be an area of debate that the evidence is too scanty to securely evaluate the clinical benefits of treating mild hypertension during pregnancy. The choice of the antihypertensive agents depends on individual clinician preference, the specified maternal and foetal benefits and the reproductive complications (teratogenisity, fetotoxicity and neonatal toxicity) of each particular agent. There are unequivocal evidences that Magnesium sulphate is superior to other agents in reducing recurrent eclamptic seizures. There is a strong recent evidence recommended that magnesium sulphate should be considered for women with pre-eclampsia for whom there is concern about the risk of eclampsia.
Export Options
About this article
Cite this article as:
Afifi Y. and Churchill D., Pharmacological Treatment of Hypertension in Pregnancy, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454487
DOI https://dx.doi.org/10.2174/1381612033454487 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers
Current Pharmaceutical Design The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Psychological Stress and the Development of Heart Disease
Current Psychiatry Reviews Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Passive Smoking, Endothelial Dysfunction and Related Markers in Healthy Individuals: An Update
Current Hypertension Reviews Secondary Prevention of Ischemic Stroke
Current Drug Targets An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound
Current Pharmaceutical Design Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Comparison Study on the Contents of Eight Flavonoids in three Different Processed Products of Scutellariae Radix using Ultra-high Performance Liquid Chromatography Coupled With Triple-Quadrupole Mass Spectrometry
Current Pharmaceutical Analysis Severe OSA Leading to Long Pauses in 24-h Holter ECG Reversed with CPAP
Current Cardiology Reviews Editorial: Pulmonary Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry